RxDoctor Payments Data

Mara Geiger, MD

Internal Medicine · Rochester Hills, MINPI 1003806241

Payments from drug & device makers

$614in general payments, 2019–2025

Across 27 payments — averaging $22.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$279
  • AbbVie$117
  • Johnson & Johnson$99
  • Astellas Pharma US Inc$53
  • GSK$28
  • Novo Nordisk$23
  • plus $15 from 1 others

What the payments were for

  • Consulting fees$17529%
  • Food & beverage$43971%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$614 in reported general payments places this provider in the 65th percentile of 4,567 internal medicine providers in Michigan.

See all internal medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$69,057
Medicare patients
226
Services billed
2,194

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide38$51,855
EliquisApixaban44$51,145
OzempicSemaglutide30$50,644
JanuviaSitagliptin Phosphate31$47,499
XareltoRivaroxaban26$37,181
JardianceEmpagliflozin18$23,072
Raloxifene Hcl129$7,009
Metoprolol Succinate309$6,745
Atorvastatin Calcium418$5,375
Levothyroxine Sodium454$5,157
ShingrixVaricella-Zoster Ge/As01b/Pf21$4,716
Rosuvastatin Calcium247$4,450
Omeprazole216$3,552
Adacel TdapDiph,pertuss(Acell),tet Vac/Pf47$3,461
SynthroidLevothyroxine Sodium37$3,246

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$23$50,64430 claims
Johnson & JohnsonXarelto$99$37,18126 claims
GSKShingrix$28$4,71621 claims
AbbVieSynthroid$117$3,24637 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 4,567 internal medicine providers in Michigan.

Other internal medicine in Rochester Hills

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →